Treatment With OpRegen Shows Improvement in Visual Acuity, Cell Persistence in Dry AMD

Video

New data from cohort 4 showed outer retinal restoration following treatment with OpRegen.

New data from the phase 1 clinical trial examining OpRegen in patients with dry age-related macular degeneration (AMD) show that the subretinal cell therapy may help improve or maintain visual acuity in this patient population, according to a presentation made at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado May 1-4, 2022 and virtually May 11-12, 2022.

The findings, presented by Allen C. Ho, MD, director of retina research and attending surgeon at Wills Eye Hospital, also demonstrated good persistence of OpRegen transplanted cells via alterations in drusen appearance, subretinal pigmentation, and hyper-reflective areas. In addition, in patients whose atrophic areas were extensively covered by the cell suspension (4/12), signs of outer retinal restoration and reduction in geographic atrophy were observed compared with baseline imaging.

OpRegen has been generally well-tolerated with no unexpected adverse events.

In an interview with CGTLive, lead investigator Ho details the findings from this latest analysis and extrapolates the potential of this therapy in dry AMD.

REFERENCE
Ho A, Banin E, Barak A, et al. Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD). Presented at: 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 1-4, 2022, Denver, CO; May 11-12, 2022, virtual.
Recent Videos
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Related Content
© 2024 MJH Life Sciences

All rights reserved.